Biogen Begins Phase III Felzartamab Study for Third Kidney Disease

Biogen (BIIB) has initiated Phase III dosing for felzartamab, an anti-CD38 antibody acquired last year through its HI-Bio acquisition, targeting primary membranous nephropathy (PMN). This global PROMINENT study will enroll approximately 180 moderate-to-high-risk PMN patients, comparing felzartamab to tacrolimus, addressing a significant unmet medical need as PMN currently lacks approved therapies and existing treatments often fail. The move follows promising Phase II results indicating antibody reduction and improved kidney markers, with top-line data expected in 2029; however, Biogen's shares are down 17.9% year-to-date.

Analysis

Biogen has initiated a Phase III trial for felzartamab in primary membranous nephropathy (PMN), a strategic pipeline advancement following its acquisition of HI-Bio. This addresses a significant unmet medical need, as PMN affects approximately 36,000 people in the U.S. and currently has no approved therapies. The PROMINENT study will compare felzartamab against the immunosuppressant tacrolimus, building on promising Phase II data where the drug demonstrated a rapid, significant reduction in aPLA2R antibody levels and a manageable safety profile. However, this clinical progress is set against a backdrop of considerable challenges. The expected top-line data readout is not until 2029, positioning this as a very long-term value driver with no near-term impact on fundamentals. This extended timeline is compounded by the stock's severe underperformance, with shares down 17.9% year-to-date, lagging the industry's 3.6% decline, and a 'Sell' rating from the source, which contrasts Biogen's outlook with peers showing stronger momentum.

Key Decisions for Investors

• Investors should recognize the felzartamab trial as a very long-term catalyst, as top-line data is not anticipated until 2029, meaning it will not address the stock's current underperformance.
• Given the stock's 17.9% year-to-date decline and the provided 'Sell' rating, any investment thesis based on this pipeline development should be viewed as a high-risk, long-duration strategy.
• It is prudent to monitor progress in Biogen's other late-stage trials for felzartamab to gauge overall execution, while acknowledging that capital may find more immediate momentum in biotech peers with stronger near-term catalysts and more favorable analyst estimates.